Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway

Kosuke Ogawa, Qiushi Lin, Le Li, Xuewei Bai, Xuesong Chen, Hua Chen, Rui Kong, Yongwei Wang, Hong‐Jian Zhu, Fuliang He, Qinggang Xu, Lianxin Liu, Min Li, Songhua Zhang, Katsuya Nagaoka, Rolf I. Carlson, Howard Safran, Kevin P. Charpentier, Bei Sun, Jack R. Wands, Xiaoqun DongJournal of Hematology & Oncology 2019 · DOI

TL;DR

This study reveals that Aspartate β-hydroxylase (ASPH) is a key driver of pancreatic cancer metastasis by activating the SRC signaling pathway. Targeting this ASPH-SRC axis with a novel small molecule inhibitor significantly reduces tumor growth and metastasis in preclinical models, offering a promising therapeutic strategy for this deadly disease.

What Problem Does This Paper Address?

Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), is notoriously aggressive and has a dismal prognosis. A major challenge in treating PDAC is its high propensity for metastasis, where cancer cells spread from the primary tumor to distant organs. While the molecular mechanisms underlying this aggressive metastatic behavior are not fully understood, it's known that signaling pathways crucial for embryonic development can be reactivated in cancer. This paper investigates the role of Aspartate β-hydroxylase (ASPH), an enzyme previously implicated in embryonic cell motility, in promoting PDAC pathogenesis and metastasis. The authors aim to elucidate how ASPH contributes to malignant phenotypes and to identify potential therapeutic targets to inhibit its metastatic potential.

Methods

The researchers employed a multi-faceted approach to investigate ASPH's role in PDAC metastasis. They utilized various in vitro techniques including:

  • Cell line manipulation: Creating cell lines that overexpress ASPH or have ASPH knocked out (KO) using lentiviral systems and CRISPR-Cas9 technology.
  • Migration and Invasion Assays: Standard Boyden chambers and Matrigel-coated chambers were used to assess 2D migration and invasion.
  • 3D Culture Models: Pancreatosphere formation and 3D spheroid invasion assays were conducted to mimic tumor microenvironments and invasion.
  • Invadopodia Assays: Techniques involving gelatin degradation and immunofluorescence were used to study invadopodia formation and function.
  • Co-immunoprecipitation and Western Blotting: These techniques were used to investigate protein-protein interactions (specifically ASPH with ADAM12/15) and to analyze the activation status of signaling molecules like SRC and FAK.
  • In vitro Metastasis Assay: A novel assay was developed to mimic the entire metastatic cascade, from intravasation through endothelial cells to colonization at distant sites.

Furthermore, they employed in vivo models:

  • Patient-Derived Xenograft (PDX) Models: PDAC tumors from patients were implanted into immunocompromised mice (NSG mice) to create models that closely resemble human disease, including spontaneous metastasis.
  • Pharmacological Inhibition: A third-generation small molecule inhibitor (MO-I-1182) specifically targeting ASPH's enzymatic activity was used to evaluate its therapeutic effects in vitro and in vivo.
  • Immunohistochemistry (IHC) and qRT-PCR: These techniques were used to assess the expression levels of ASPH and its associated signaling molecules in both cell lines and patient-derived tumors.
  • Statistical Analysis: Kaplan-Meier plots, log-rank tests, and Cox proportional hazards regression models were used to evaluate the prognostic value of ASPH network components in patient data.

Datasets

The study utilized several datasets:

  • Human Pancreatic Cancer Cell Lines: MIA-Paca2, AsPC-1, and HPAFII cell lines were used for in vitro experiments.
  • Patient-Derived Xenograft (PDX) Models: Tumors from six PDAC patients were used to establish PDX models, which were then serially passaged. These models were crucial for evaluating in vivo therapeutic efficacy and recapitulating metastatic phenotypes.
  • Human Tissue Microarray: A cohort of 166 PDAC patient specimens was used for immunohistochemical analysis to correlate ASPH network component expression with clinical outcomes.

Key Insights and Ideas

  • ASPH as a Metastasis Driver: The study strongly implicates ASPH as a critical factor promoting aggressive phenotypes in PDAC, including epithelial-mesenchymal transition (EMT), invasion, stemness, and ultimately, metastasis.
  • ASPH-SRC Axis Activation: A key finding is that ASPH directly interacts with ADAM12/15, leading to the activation of the SRC signaling pathway. This axis appears to be central to ASPH's pro-metastatic effects.
  • Invadopodia as Key Effectors: The ASPH-SRC axis drives the formation and function of invadopodia, specialized cellular structures that degrade the extracellular matrix, enabling cancer cell invasion and metastasis.
  • Therapeutic Vulnerability: The development of a specific small molecule inhibitor (MO-I-1182) targeting ASPH's enzymatic activity demonstrates that this axis is a druggable target. This inhibitor effectively reversed malignant phenotypes in vitro and significantly inhibited tumor growth and metastasis in vivo.
  • Prognostic Biomarker Potential: The expression levels of ASPH and its associated SRC pathway components were found to be significantly correlated with patient survival, suggesting their potential as biomarkers for PDAC prognosis.
  • Relevance to Embryonic Pathways: The reactivation of embryonic signaling pathways, like those involving ASPH, in adult cancer highlights a common theme in tumorigenesis.

Key Results

  • Overexpression of ASPH in MIA-Paca2 cells significantly increased migration, 2D/3D invasion, and pancreatosphere formation.
  • ASPH directly interacts with ADAM12 and ADAM15, leading to the activation of SRC signaling (measured by pSRC Y416).
  • Inhibition of SRC signaling with Dasatinib significantly reduced ASPH-mediated aggressive phenotypes.
  • A novel in vitro metastasis assay showed that ASPH significantly boosted transendothelial migration, extravasation, and colonization, which were reversed by the ASPH inhibitor MO-I-1182.
  • In PDX models, MO-I-1182 treatment substantially inhibited primary tumor growth and pulmonary metastasis.
  • Higher expression levels of ASPH, activated SRC, ADAM12, and MMPs were significantly correlated with poorer overall survival in PDAC patients. A combined score of these unfavorable molecules showed a strong predictive power for prognosis.

Limitations and Future Work

The authors acknowledge several limitations:

  • Specific Interaction Sites: The precise binding sites for ASPH on ADAM12/15 and the specific hydroxylation sites by ASPH remain to be elucidated.
  • Functional Changes of ADAMs: The dynamic configurational or functional changes of ADAM12/15 upon hydroxylation by ASPH, and whether this is required for SRC activation, require further exploration.
  • Retrospective Study Design: The prognostic value of the ASPH network was assessed in a single-center retrospective study, which may introduce sampling bias.
  • Limited Protein Investigation: Only a subset of proteins within the ASPH network was investigated, and potential false positives from multiple comparisons are a possibility.

Future work could focus on:

  • Elucidating the detailed molecular mechanisms of ASPH-ADAM interaction and its impact on SRC activation.
  • Developing more comprehensive predictive models using a wider range of proteins.
  • Further validating ASPH and its network components as reliable biomarkers for early diagnosis and prognosis.
  • Continuing the development and clinical translation of ASPH-targeting therapies.

Summary updated

Abstract

Targeting the ASPH-SRC axis, which is essential for propagating multi-step PDAC metastasis, may specifically/substantially retard development/progression and thus improve prognosis of PDAC.
BibTeX
@article{ogawa2019aspartate,
  author = {Kosuke Ogawa and Qiushi Lin and Le Li and Xuewei Bai and Xuesong Chen and Hua Chen and Rui Kong and Yongwei Wang and Hong‐Jian Zhu and Fuliang He and Qinggang Xu and Lianxin Liu and Min Li and Songhua Zhang and Katsuya Nagaoka and Rolf I. Carlson and Howard Safran and Kevin P. Charpentier and Bei Sun and Jack R. Wands and Xiaoqun Dong},
  title = {{Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway}},
  journal = {Journal of Hematology \& Oncology},
  year = {2019},
  doi = {10.1186/s13045-019-0837-z},
}
Figure